In diabetic peripheral neuropathy, alpha-lipoic acid probably has little or no effect on neuropathy symptoms compared with placebo. That is the conclusion of a 2024 Cochrane review of three placebo-controlled randomized trials in 816 adults with type 1 or type 2 diabetes, which found a mean difference of −0.16 points on symptom scores at six months and low-certainty evidence of little or no effect on impairment [1]. An American Family Physician summary of the same review reported the same picture at both six and 24 months [2].
That does not make alpha-lipoic acid harmful, and it does not answer every neuropathy question. It means that if your goal is a noticeable change in burning or numbness from diabetic peripheral neuropathy, the trial record does not support expecting it from this supplement on its own.
What “little or no effect” means in plain language
Trial wording can feel evasive, so here is the translation. Across the studied population — adults with diabetes and diabetic peripheral neuropathy, mean age 57.8 years, treated for at least six months at doses between 600 and 1,800 mg per day — the average result on alpha-lipoic acid was close to the average result on placebo [1].
The reviewers also reported little or no difference in adverse events that caused people to stop treatment [1][2]. So the honest summary is not that this supplement is dangerous. It is that it is unlikely to change how your feet feel.
What the review actually measured
The primary outcome was change in neuropathy symptoms six months after randomization, measured with validated instruments such as the Total Symptom Score. Secondary outcomes included symptoms at 24 months, impairment at six and 24 months, and adverse events leading to discontinuation [1].
Certainty was downgraded because of loss to follow-up and imprecision, particularly for impairment [1]. That distinction is worth keeping: the finding is not that the supplement was proven useless, it is that no signal appeared on evidence of moderate and low certainty.
Why one supplement rarely moves a neuropathy
Peripheral neuropathy is a category, not a diagnosis. Nerve injury can be driven by metabolic stress, nutritional deficiency, autoimmune activity, toxic exposure or structural compression, and those drivers do not answer to the same intervention.
That is why the first question in our clinic is not which supplement to add, it is which driver is doing the most damage right now. You can read how we approach the drivers that commonly get missed in the hidden drivers of peripheral neuropathy.
When the driver is metabolic
When the dominant driver is metabolic, the plan has two parallel goals: reduce the ongoing metabolic pressure on nerve fibers and their microcirculation, and support the nerve environment while that pressure comes down. A supplement added on top of an unchanged metabolic picture is working against the current.
For the chemistry behind that, see our explainer on glycation and how sugar damages nerves.
When the driver is not metabolic
Nutritional deficits, gluten-associated patterns, toxic and environmental exposures, autoimmune activity and chemotherapy-related nerve injury all produce peripheral nerve symptoms, and none of them were the population studied in the alpha-lipoic acid trials.
A label of idiopathic usually means the driver has not been mapped yet, not that no driver exists. That is a reason to keep looking, not a reason to rotate supplements.
What we do instead of guessing
We perform electrodiagnostic testing (EMG and nerve conduction studies) on site, so nerve conduction findings are interpreted alongside your history rather than arriving as a separate report weeks later. We pair that with metabolic and nutritional evaluation to check whether the terrain has what nerves need.
Where in-clinic therapy is appropriate, our confirmed options include class 4 photobiomodulation, class 3B cold laser and whole-body infrared. These are used inside a driver-matched plan rather than as a standalone answer, and we do not promise nerve regeneration or reversal of established nerve damage.
Where alpha-lipoic acid can still sit in a plan
Some patients arrive already taking it and tolerate it well. Our position is that it can remain one element of metabolic and nutritional support as long as it is not displacing the work that actually changes the driver, and that the trial evidence should set your expectations for what it will do.
Frequently asked questions
Does alpha-lipoic acid help diabetic peripheral neuropathy?
Probably not to a degree you would notice. A 2024 Cochrane review of three placebo-controlled trials in 816 adults with diabetes concluded that alpha-lipoic acid probably has little or no effect on neuropathy symptoms at six months, and may have little or no effect on impairment [1]. Our approach when diabetes is the driver is described on our diabetic peripheral neuropathy treatment page.
Does taking it for longer work better?
Not according to the published record. An American Family Physician summary of the same Cochrane review reported little or no effect compared with placebo on symptoms and impairment at both six and 24 months [2]. When a nutritional driver is the real problem, correcting that deficiency is a different question — see functional B12 deficiency and neuropathy.
Do these results apply to me if my neuropathy is not from diabetes?
No. The trials enrolled adults with type 1 or type 2 diabetes and diabetic peripheral neuropathy [1], so the finding cannot be transferred to autoimmune, toxic, nutritional or idiopathic drivers. Burning pain that persists when routine nerve conduction testing looks close to normal points somewhere else — see small fiber neuropathy symptoms and testing.
If not a supplement, what is the first useful step?
Identifying which driver is active, then matching testing to that pattern. We perform electrodiagnostic testing (EMG and nerve conduction studies) on site and read it alongside metabolic and nutritional evaluation rather than adding one variable at a time. See our neuropathy services.
Start with the Nerve Damage Score
The Nerve Damage Score is a free five-question assessment that helps identify which driver is most likely behind your symptoms, so your evaluation starts with a direction instead of a guess.
Regenerve, 4477 Woodson Rd #104, St. Louis, MO 63134. Serving the St. Louis region, Missouri and Illinois, minutes from St. Louis Lambert International Airport.
Sources
- Baicus C, Purcarea A, von Elm E, Delcea C, Furtunescu FL. “Alpha-lipoic acid for diabetic peripheral neuropathy.” Cochrane Database of Systematic Reviews, 2024, Issue 1, Art. No.: CD012967. Published 11 January 2024. DOI: 10.1002/14651858.CD012967.pub2. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012967.pub2/full — cited for the three included placebo-controlled trials, 816 adult participants with type 1 or type 2 diabetes, mean age 57.8 years, doses of 600–1,800 mg per day, the −0.16-point symptom difference and −1.02-point impairment difference at six months, the outcome definitions, and the certainty downgrades for loss to follow-up and imprecision.
- Abuali SM, Frasca DJ. “Alpha-Lipoic Acid for Diabetic Peripheral Neuropathy.” American Family Physician, February 2025;111(2):119–120. https://www.aafp.org/afp/2025/0200/mbtn-alpha-lipoic-acid-diabetic-peripheral-neuropathy — cited for little or no effect versus placebo on symptom reduction and impairment at six and 24 months, and little or no difference in adverse events.